These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29327400)

  • 1. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
    Mietlicki-Baase EG; Liberini CG; Workinger JL; Bonaccorso RL; Borner T; Reiner DJ; Koch-Laskowski K; McGrath LE; Lhamo R; Stein LM; De Jonghe BC; Holz GG; Roth CL; Doyle RP; Hayes MR
    Diabetes Obes Metab; 2018 May; 20(5):1223-1234. PubMed ID: 29327400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
    Tinsley IC; Borner T; Swanson ML; Chepurny OG; Doebley SA; Kamat V; Sweet IR; Holz GG; Hayes MR; De Jonghe BC; Doyle RP
    J Med Chem; 2021 Mar; 64(6):3479-3492. PubMed ID: 33677970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
    Borner T; Shaulson ED; Tinsley IC; Stein LM; Horn CC; Hayes MR; Doyle RP; De Jonghe BC
    Diabetes Obes Metab; 2020 Oct; 22(10):1729-1741. PubMed ID: 32410372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.
    Borner T; Workinger JL; Tinsley IC; Fortin SM; Stein LM; Chepurny OG; Holz GG; Wierzba AJ; Gryko D; Nexø E; Shaulson ED; Bamezai A; Da Silva VAR; De Jonghe BC; Hayes MR; Doyle RP
    Cell Rep; 2020 Jun; 31(11):107768. PubMed ID: 32553160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.
    Song X; Sun X; Hao H; Han Q; Han W; Mu Y
    Stem Cells Dev; 2021 May; 30(9):502-514. PubMed ID: 33677993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.
    Barrera JG; D'Alessio DA; Drucker DJ; Woods SC; Seeley RJ
    Diabetes; 2009 Dec; 58(12):2820-7. PubMed ID: 19741167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
    Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
    Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia.
    Swick JC; Alhadeff AL; Grill HJ; Urrea P; Lee SM; Roh H; Baird JP
    Neuropsychopharmacology; 2015 Jul; 40(8):2001-14. PubMed ID: 25703200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells.
    Son S; Park EJ; Kim Y; Lee KC; Na DH
    Int J Biochem Cell Biol; 2018 Dec; 105():13-19. PubMed ID: 30273669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats.
    Krieger JP; Santos da Conceição EP; Sanchez-Watts G; Arnold M; Pettersen KG; Mohammed M; Modica S; Lossel P; Morrison SF; Madden CJ; Watts AG; Langhans W; Lee SJ
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R708-R720. PubMed ID: 29847161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.
    Bornebusch AB; Fink-Jensen A; Wörtwein G; Seeley RJ; Thomsen M
    eNeuro; 2019; 6(2):. PubMed ID: 31058214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.
    Hayes MR; Kanoski SE; De Jonghe BC; Leichner TM; Alhadeff AL; Fortin SM; Arnold M; Langhans W; Grill HJ
    Am J Physiol Regul Integr Comp Physiol; 2011 Nov; 301(5):R1479-85. PubMed ID: 21849636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.